These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
758 related articles for article (PubMed ID: 23695200)
1. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. Leuppi JD; Schuetz P; Bingisser R; Bodmer M; Briel M; Drescher T; Duerring U; Henzen C; Leibbrandt Y; Maier S; Miedinger D; Müller B; Scherr A; Schindler C; Stoeckli R; Viatte S; von Garnier C; Tamm M; Rutishauser J JAMA; 2013 Jun; 309(21):2223-31. PubMed ID: 23695200 [TBL] [Abstract][Full Text] [Related]
2. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial. van Velzen P; Ter Riet G; Bresser P; Baars JJ; van den Berg BTJ; van den Berg JWK; Brinkman P; Dagelet JWF; Daniels JMA; Groeneveld-Tjiong DRGL; Jonkers RE; van Kan C; Krouwels FH; Pool K; Rudolphus A; Sterk PJ; Prins JM Lancet Respir Med; 2017 Jun; 5(6):492-499. PubMed ID: 28483402 [TBL] [Abstract][Full Text] [Related]
3. Short versus conventional term glucocorticoid therapy in acute exacerbation of chronic obstructive pulmonary disease - the "REDUCE" trial. Schuetz P; Leuppi JD; Tamm M; Briel M; Bingisser R; Dürring U; Müller B; Schindler C; Viatte S; Rutishauser J Swiss Med Wkly; 2010; 140():w13109. PubMed ID: 21136333 [TBL] [Abstract][Full Text] [Related]
4. Reduction of corticosteroid use in outpatient treatment of exacerbated COPD - Study protocol for a randomized, double-blind, non-inferiority study, (The RECUT-trial). Urwyler P; Boesing M; Abig K; Cattaneo M; Dieterle T; Zeller A; Bachler H; Markun S; Senn O; Merlo C; Essig S; Ullmer E; Rutishauser J; Schuurmans MM; Leuppi JD Trials; 2019 Dec; 20(1):727. PubMed ID: 31842993 [TBL] [Abstract][Full Text] [Related]
5. Predictors of re-exacerbation after an index exacerbation of chronic obstructive pulmonary disease in the REDUCE randomised clinical trial. Engel B; Schindler C; Leuppi JD; Rutishauser J Swiss Med Wkly; 2017; 147():w14439. PubMed ID: 28634972 [TBL] [Abstract][Full Text] [Related]
6. Comparison of two systemic steroid regimens for the treatment of COPD exacerbations. Ceviker Y; Sayiner A Pulm Pharmacol Ther; 2014 Apr; 27(2):179-83. PubMed ID: 23518215 [TBL] [Abstract][Full Text] [Related]
7. Effect of sequential treatment with TCM syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and AECOPD risk window. Jiansheng L; Haifeng W; Suyun L; Hailong Z; Xueqing Y; Xiaoyun Z; Fengsen L; Xianmei Z; Zikai S; Yimin M; Lijun M; Yijie Z; Guojun Z; Bingxiang T Complement Ther Med; 2016 Dec; 29():109-115. PubMed ID: 27912934 [TBL] [Abstract][Full Text] [Related]
8. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127 [TBL] [Abstract][Full Text] [Related]
9. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Niewoehner DE; Erbland ML; Deupree RH; Collins D; Gross NJ; Light RW; Anderson P; Morgan NA N Engl J Med; 1999 Jun; 340(25):1941-7. PubMed ID: 10379017 [TBL] [Abstract][Full Text] [Related]
10. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766 [TBL] [Abstract][Full Text] [Related]
11. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586 [TBL] [Abstract][Full Text] [Related]
12. Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial. Ramakrishnan S; Jeffers H; Langford-Wiley B; Davies J; Thulborn SJ; Mahdi M; A'Court C; Binnian I; Bright S; Cartwright S; Glover V; Law A; Fox R; Jones A; Davies C; Copping D; Russell RE; Bafadhel M Lancet Respir Med; 2024 Jan; 12(1):67-77. PubMed ID: 37924830 [TBL] [Abstract][Full Text] [Related]
13. TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Aaron SD; Vandemheen KL; Maltais F; Field SK; Sin DD; Bourbeau J; Marciniuk DD; FitzGerald JM; Nair P; Mallick R Thorax; 2013 Feb; 68(2):142-8. PubMed ID: 23161645 [TBL] [Abstract][Full Text] [Related]
14. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis. Blasi F; Schaberg T; Centanni S; Del Vecchio A; Rosignoli MT; Dionisio P Pulm Pharmacol Ther; 2013 Oct; 26(5):609-16. PubMed ID: 23538168 [TBL] [Abstract][Full Text] [Related]
15. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS; Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680 [TBL] [Abstract][Full Text] [Related]
16. Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial. Devereux G; Cotton S; Nath M; McMeekin N; Campbell K; Chaudhuri R; Choudhury G; De Soyza A; Fielding S; Gompertz S; Haughney J; Lee AJ; MacLennan G; Morice A; Norrie J; Price D; Short P; Vestbo J; Walker P; Wedzicha J; Wilson A; Wu O; Lipworth BJ JAMA; 2024 Aug; 332(6):462-470. PubMed ID: 38762800 [TBL] [Abstract][Full Text] [Related]
17. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Uzun S; Djamin RS; Kluytmans JA; Mulder PG; van't Veer NE; Ermens AA; Pelle AJ; Hoogsteden HC; Aerts JG; van der Eerden MM Lancet Respir Med; 2014 May; 2(5):361-8. PubMed ID: 24746000 [TBL] [Abstract][Full Text] [Related]
18. The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. Vermeersch K; Gabrovska M; Deslypere G; Demedts IK; Slabbynck H; Aumann J; Ninane V; Verleden GM; Troosters T; Bogaerts K; Brusselle GG; Janssens W Int J Chron Obstruct Pulmon Dis; 2016; 11():687-96. PubMed ID: 27099485 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of Jia Wei Bushen Yiqi formulas as an adjunct therapy to systemic glucocorticoids on acute exacerbation of COPD: study protocol for a randomized, double-blinded, multi-center, placebo-controlled clinical trial. Kong Q; Mo S; Wang W; Tang Z; Wei Y; Du Y; Liu B; Kong L; Lv Y; Dong J Trials; 2020 Sep; 21(1):760. PubMed ID: 32883322 [TBL] [Abstract][Full Text] [Related]